What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2)

Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Forciea, Mary Ann; Abraham, George M.; Miller, Matthew C.; Obley, Adam J.; Humphrey, Linda L.

doi:10.7326/m21-3272

Cited by 1 publication

(1 citation statement)

References 83 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vast majority of SARS‐CoV‐2‐infected individuals seroconvert and develop nAbs (91%–99%). 182 , 183 , 184 While nAb titers decline during the first few months post‐infection, nAb titers stabilize between 4 and 6 months post‐infection, with little evidence of decline thereafter. After the initial decay phase (dominated by short‐lived B PC ), the estimate SARS‐CoV‐2 nAb t 1/2 is 254 days.…”

Section: Antibody Durability To Sars‐cov ‐2 Infect...mentioning

confidence: 99%

Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines

Sette

Crotty

2022

Immunological Reviews

156

View full text Add to dashboard Cite

Immunological memory is the basis of protective immunity provided by vaccines and previous infections. Immunological memory can develop from multiple branches of the adaptive immune system, including CD4 T cells, CD8 T cells, B cells, and long-lasting antibody responses. Extraordinary progress has been made in understanding memory to SARS-CoV-2 infection and COVID-19 vaccines, addressing development; quantitative and qualitative features of different cellular and anatomical compartments; and durability of each cellular component and antibodies. Given the sophistication of the measurements; the size of the human studies; the use of longitudinal samples and cross-sectional studies; and head-to-head comparisons between infection and vaccines or between multiple vaccines, the understanding of immune memory for one year to SARS-CoV-2 infection and vaccines already supersedes that of any other acute infectious disease. This knowledge may help inform public policies regarding COVID-19 and COVID-19 vaccines, as well as the scientific development of future vaccines against SARS-CoV-2 and other diseases.

show abstract

Section: Antibody Durability To Sars‐cov ‐2 Infect...mentioning

confidence: 99%